Biotechnology firm GeoVax Labs is set to provide critical updates on its COVID-19 vaccine program during the Emerging Growth Conference on April 16, 2025. Chairman and CEO David Dodd will deliver a presentation focusing on the recent termination of the company's contract with the Biomedical Advanced Research and Development Authority (BARDA).
The live, interactive online event will offer investors and interested parties an opportunity to gain direct insights into the company's current strategic positioning. Dodd is scheduled to speak at 3:40 pm ET and will address questions submitted in advance or during the conference.
GeoVax's lead clinical program, GEO-CM04S1, is a next-generation COVID-19 vaccine currently undergoing three Phase 2 clinical trials. These trials are examining the vaccine's potential for immunocompromised patients, as a booster for chronic lymphocytic leukemia patients, and as a more robust booster for individuals previously vaccinated with mRNA vaccines.
The conference presentation comes at a critical juncture for the company, potentially offering clarity on the implications of the BARDA contract termination and the future trajectory of its vaccine development efforts. Investors and healthcare industry observers will likely be keen to understand how this development might impact GeoVax's research and commercial strategies.
